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Abstract
Introduction: Substance use and depression co-occurrence is a frequent phenomenon and an important public health
concern. Given the clinical implications and the high prevalence of both disorders, effective interventions are needed.
Methods: The aim of this study is to review Behavioural Activation (BA) intervention effects to improve substance use
behaviour and depression. A systematic review was conducted using MEDLINE, EMBASE, and PsycINFO. The Effective
Public Health Practice Project Quality Assessment Tool (EPHPP) was used to assess the methodological quality of included
studies. Two authors independently screened titles and abstracts, reviewed selected studies, and extracted data.
Results: Of the 7286 studies identified, eight met inclusion criteria. Designs of the studies included six randomized
controlled trials (RCTs), and two pre-post design studies. One trial received weak methodological quality, six moderate,
and one strong. Three studies addressed smoking behaviour; two targeted opiate dependence; two focused on alcohol/
drug dependence; and, one on crystal methamphetamine abuse. Results showed that BA had a positive effect on
substance use outcomes in seven of the eight reviewed studies, and improved depression over time in six studies.
Conclusions: Although studies conducted so far are limited by their heterogeneity and sample sizes, results are
promising. There is a need of well controlled and powered studies to establish and to confirm the effectiveness of BA for
the treatment of substance use and depression. Future studies should include stronger methodological designs, larger
sample sizes, and long-term follow-ups.
Trial registration: PROSPERO registration number: CRD42016039412.
Keywords: Behaviour therapy, Behavioural activation, Substance use disorder, Depression, Systematic review
Introduction
Substance use disorders (SUDs) and mental health disor-
ders are significant contributors to the global burden of
disease, and their impact is increasing over the years both
in high-income and low-to-middle-income countries [1].
In fact, prevalence of SUDs reaches the 8.7% of U.S.
adults, and among the most prevalent mental disorders
stand out depression, with about 6.7% of U.S. adults hav-
ing a major depressive episode during the past year [2].
In the general population, co-occurrence of SUDs (in-
cluding alcohol, tobacco, cannabis, cocaine, and other
illicit drugs) and depression is a common and well docu-
mented phenomenon [2–6]. In this sense, a meta-ana-
lysis of epidemiological studies of the comorbidity of
SUDs and mood and anxiety disorders [7], found a strong
association between major depression and several SUDs
such as alcohol use disorders (pooled Odd Ratio [OR] =
2.42) and illicit drug use disorder (pooled OR = 3.80).
Similarly, research has shown that people with SUDs is
more likely to have a major depressive disorder, compare
to those without SUDs, even after controlling for sociode-
mographic characteristics and additional psychiatric co-
morbidity (adjusted OR = 1.2 and 1.3, respectively) [8].
Moreover, depression has also been found consistently
higher in smokers compared to never smokers (OR =
1.50) and former smokers (OR = 1.76) [9].
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Regarding people seeking substance use treatment, de-
pression is a particular concern because of its high
prevalence and clinical implications [10–12]. Specifically,
depression has been related to greater physical, psycho-
logical, and social impairments, poorer treatment adher-
ence, and worse treatment outcomes [13, 14].
Importantly, several studies have found that depression
decreases the likelihood of abstinence in people under-
going substance use treatment [15–17].
Previous literature has suggested the existence of com-
mon features between substance use disorders and
depression. For example, studies have highlighted the
key role of positive reinforcement in both conditions
[18, 19]. Positive reinforcement can be defined as the
process by which a response is followed by a stimulus,
and response probability increases. Positive reinforcers
are fundamental in this process, and they can be defined
as incentives, stimulus, and/or activities that are pre-
ferred for an individual. From a behavioural perspective,
depression occurs when positive reinforcement for
healthy behaviours decreases, there is a low availability
of positive reinforcers in the environment, and/or when
there is a lack of behavioural skills to achieve them [20].
In the case of SUDs, studies have found that people with
SUDs are less engaged in non-drug-related activities and
have less alternative positive reinforcers in their environ-
ment (e.g., social activities) [18, 21–23]. Indeed, previous re-
search have demonstrated that engaging in alternative
activities, as exercise or creative activities, was associated
with reductions in substance use consumption [24, 25]. In
this line, following the approach of behavioural economic
interventions, Murphy et al. [26] found that adding a com-
ponent addressing substance-free activities (academic,
career-related, and leisure activities) to an alcohol brief mo-
tivational interviewing session for heavy drinking among
college students, was associated with reductions in alcohol
problems. Similarly, Reynolds et al. [27] integrated a BA ap-
proach within a standard college orientation program and
found a significant reduction in the consequences associ-
ated with alcohol drinking (e.g., alcohol-related injuries, so-
cial and psychological problems).
Due to the high comorbidity between substance use
and depression, and the impact of depression on sub-
stance use treatment outcomes, it is important to ad-
dress both disorders simultaneously. There exist
different treatments for depression and SUDs, as cogni-
tive behavioural therapy (CBT) or contingence manage-
ment interventions (CM) [28, 29]. Although some
preliminary findings indicate that these interventions
have certain efficacy in treating both conditions, there is
a need to continue developing and testing interventions
for both disorders [30, 31].
Behavioural Activation (BA), which was originally con-
ceptualized as a treatment for depression, is emerging as
an option for SUDs. This intervention has its roots in
the traditional behaviourism approach, but a renewed
interest appeared since the study conducted by Jacob-
son et al. [32]. In such study, the authors isolated the
BA component of cognitive therapy (CT) to deter-
mine whether BA by itself could be as effective as
CT for depression treatment. Their results confirmed
the equal effectiveness of BA and CT in reducing de-
pressive symptoms, pointing out that BA is more par-
simonious and less complex than CT. Nowadays, BA
is considered a well-established and cost-effective
intervention for depression [33, 34].
BA characteristics, and the focus on providing reward-
ing experiences in daily life different from substance use,
make of this approach a potential intervention to in-
crease substance use abstinence outcomes and to relapse
prevention [35]. Since BA effectiveness has been widely
demonstrated in depression treatment, we sought to ex-
tend previous findings by analyzing whether BA would
improve comorbid substance use outcomes as well.
Therefore, the aim of this review was to analyze the re-
sults of BA intervention on (i) substance use, abstinence,
or relapse; and on (ii) depression symptom outcomes in
individuals with substance use and depression.
Method
Search strategy
This systematic review followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis
(PRISMA) statement [36], and the review protocol
was registered with PROSPERO (CRD42016039412).
The PRISMA checklist is provided in Additional file 1.
The following electronic databases were used for the
literature search, with alterations to the search
strategy for specific databases: MEDLINE, PsycINFO,
and Excerpta Medica DataBase (EMBASE). The litera-
ture search strategy for the three electronic databases,
including any search limits used, is provided in
Additional file 2. A search of reference lists of in-
cluded studies and Google Scholar (first 200 citations
published online between January 2000 and May
2018) was undertaken. We included studies published
in English and Spanish, and all years available in the
selected databases (up to May 2018).
Study selection criteria
Study characteristics
The following study designs were included: (i) experimental
studies (randomized controlled trials, quasi-randomized tri-
als, controlled clinical trials); (ii) quasi-experimental studies
(interrupted time series, before-and-after studies) and; (iii)
observational studies (cohort studies and case-control stud-
ies). We excluded case series studies, research protocols, re-
view articles, and non-interventional studies.
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Participants
Participants of included studies were: (i) adult substance
users (age ≥ 18 years); (ii) with depression. For the purpose
of this review, substance users were defined as individuals
who used substances assessed by a screening question-
naire (e.g., Substance Use Weekly Inventory) or as individ-
uals who met criteria for SUD by a diagnostic interview
(e.g., Structured Clinical Interview for Diagnostic and Stat-
istical Manual of Mental Disorders; SCID-DSM). Sub-
stances included alcohol, tobacco, caffeine, cannabis,
cocaine, heroin, amphetamines, ecstasy, synthetic drugs,
and non-prescription use of legal drugs (e.g., morphine,
codeine, benzodiazepines). People with depression were
defined as individuals who experienced a depressive dis-
order assessed by a structured clinical interview con-
ducted to internationally recognized standards (e.g., DSM)
or depressive symptoms established by a validated screen-
ing measure (e.g., Beck Depression Inventory).
Type of intervention
Included studies were those examining the effect of
face-to-face BA intervention on substance use and de-
pression outcomes. To define BA features, Kanter et al.
[37] reviewed the specific treatment components of BA
and identified the following: activity monitoring, assess-
ment of life goals and values, activity scheduling, skills
training, relaxation training, contingency management,
procedures targeting verbal behaviour, and procedures
targeting avoidance. Despite the broad range of tech-
niques used in BA interventions, they found that activity
monitoring and scheduling were constant components
across interventions.
Although there exist several conceptualizations of BA
[38, 39], they all focus on behaviour change through the
increase of positive reinforcement using strategies to en-
courage individuals to engage in adaptive and rewarding
activities [40]. Therefore, in this review, we used the
term ‘BA’ to cover all BA conceptualizations, including
those studies where at least activity self-monitoring and
scheduling were core elements of the intervention [37].
Exclusion criteria
Excluded studies were those in which: (i) participants
had cognitive impairment; (ii) intervention was comput-
erized or Internet-delivered; (iii) intervention did not in-
clude self-monitoring or activity scheduling; (iv) BA was
only one component of CBT and not the core treatment
element; and (v) both substance use and depression out-
comes were not included.
Outcomes
Primary outcomes were: (i) substance use (at least one
outcome related to substance use, abstinence, or re-
lapse); and (ii) depressive symptoms.
Secondary outcomes were: (i) treatment adherence
and retention; and (ii) number of quit attempts, use of
other substances, motivation to quit, health-related con-
ditions (e.g., diabetes, Human Immunodeficiency Virus,
HIV), other mental health symptoms, and healthcare
use. These variables were included as secondary out-
comes since they have demonstrated to be predictors of
treatment outcomes [41].
Study selection
Titles and abstracts retrieved by electronic searches were
exported to reference management software (RefWorks)
to remove duplicates. References were then exported to
the online software tool Covidence for screening. Titles
and abstracts were screened independently by two au-
thors (CMV and UM). Disagreements were discussed by
the two reviewers. The two reviewers (CMV and UM)
performed independently full-text screening, data ex-
traction, and quality assessment. Reasons for full text ex-
clusion were recorded and documented in a PRISMA
flow diagram (Fig. 1).
Data extraction and analysis
Data were extracted independently by CMV and UM
using a data extraction form constructed in Microsoft
Excel 2010®: study identification features, study design,
participant characteristics, sample size, intervention de-
livery mode, who delivered the intervention, whether the
intervention was individual or group sessions, group size
for group-based intervention, duration of intervention,
number of sessions, length of sessions, treatment setting,
depression outcomes, substance use outcomes, and, if
reported, information on the components of the BA
intervention. Discrepancies were resolved by discussion
between the two reviewers.
Assessment of risk of bias
The quality of the studies that met eligibility criteria was
independently assessed by two reviewers (CMV and
UM). Ratings were then reviewed to discuss discrepan-
cies. Quality assessment was conducted using the Effect-
ive Public Health Practice Project Quality Assessment
Tool (EPHPP). This is a generic tool used to evaluate
a variety of intervention study designs such as ran-
domized controlled trials (RCTs) and before-and-after
studies. This tool has been considered suitable to be
used in systematic reviews of effectiveness [42]. The
tool assesses six domains: (i) selection bias, (ii) study
design, (iii) confounders, (iv) blinding, (v) data collec-
tion method, and (vi) withdrawals/dropouts. The tool
guidelines indicate that each domain can be rated as
strong, moderate, or weak. Based on the total score
studies can be assigned a quality rating of strong,
moderate, or weak.
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Results
A total of 7286 studies were identified after duplicates
were removed. Once titles and abstracts were screened,
181 studies were selected for full text screening (Fig. 1).
Finally, a total of eight studies met inclusion criteria and
were included in the review [43–50].
Study characteristics
A complete description of study characteristics is pro-
vided in Table 1. Of the eight included studies, six were
conducted in the United States [43–45, 47–49], one in
the United Kingdom [46], and one in Spain [50]. Six
were RCTs [43, 45–47], and two were before-and-after
studies [44, 48]. Regarding the type of substance
assessed, three targeted smoking behaviour [43, 47, 50];
two targeted opiate dependence [44, 45]; two focused on
alcohol or drug dependence [46, 49]; and finally, one on
crystal methamphetamine abuse [48]. Six studies pro-
vided biochemical verification of substance use [43–45,
47, 49, 50]. The assessment points ranged from baseline
to 12 months post-intervention.
Methodological quality assessment
Overall, one study received a methodological quality rat-
ing of strong [49], six studies of moderate [43, 45–48, 50],
and one study of weak [44]. The quality assessment rat-
ings for each specific criterion and the assigned global rat-
ing are reported in Table 2. Study design and data
collection dimensions were the main strengths of included
studies, while blinding was the main weakness. Only in
two studies [47, 49] participants and research staff asses-
sing outcomes were blind to the study conditions. How-
ever, it is of note that blinding participants in behavioural
intervention studies is often not feasible, as a result of the
nature of the intervention.
The EPHPP tool provides two additional methodo-
logical dimensions (intervention integrity and analyses),
which were also considered. Only three studies provided
information about the intervention integrity by assessing
the percentage of participants who received the inter-
vention as intended: two were scored in the 80–100%
category [43, 50]; and one was scored in the less than
60% category [46]. With regard to the analysis compo-
nent, all studies used intent-to-treat analyses as appro-
priate, except for Mimiaga et al. [48] who did not
provide this information.
Effects of BA intervention in substance use and
depression outcomes
Intervention descriptions and a summary of the main
findings of the effects of BA on substance use and de-
pression outcomes are reported in Table 3.
Substance use outcomes
Two of the six RCT included found significantly higher
abstinence rates for BA compared to the control condi-
tion in each point assessment [47, 49]. Specifically,
Daughters et al. [49] reported abstinence ORs of 2.2, 2.6,
and 2.9 at 3, 6, and 12 months respectively in the BA
condition. MacPherson et al. [47] also found significant
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Fig. 1 PRISMA flowchart depicting the process of searching, selecting and screening studies according to eligibility criteria
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OR in the BA condition (OR = 4.0 at 1 week post-quit;
2.06 at 4 weeks; 2.71 at 16 weeks, and 3.59 at 26 weeks).
No significant differences in abstinence rates were
found between BA and the control conditions in the rest
of the RCT included [43, 45, 46, 50]. However, in one
study mean number of days to first lapse after discharge
was significantly higher for BA when comparing to the
control condition (62.4 vs. 31.8 days, respectively, p
= .03) [43]. Lastly, the study conducted by Delgadillo et
al. [46], found 17% increase of days abstinent after treat-
ment in the BA group. This indicates that there was a
reduction in substance use in the BA group, whereas no
change was detected in the control group [46]. Although
there was a positive trend associated with the BA condi-
tion, differences were not statistically significant (Mean
differences between-group effect size of d = 1.52, p
= .08).
Regarding the two studies that compared pre- and post-
substance use rates the results were mixed. While Carpen-
ter et al. [44] did not find changes in opiate and cocaine
use after treatment, Mimiaga et al. [48] found a significant
decrease from baseline to acute post-intervention and to
3 months post-intervention in the number of days of use
in the past 30 days (p = .010), in number of crystal meth-
amphetamine episodes in the past 3 months (p < .001),
and in number of days experiencing drug-related prob-
lems during the past 30 days (p = .005).
Depression outcomes
The majority of studies included in the present review
found a significant improvement in depression symp-
toms over time [44–48, 50]. However, most studies
showed equivalent results across treatment conditions
[45, 46, 49, 50]. Only one RCT [47] found a significant
reduction in depression symptoms for those participants
randomized to BA compared to the control group (B =
− 1.99, SE = 0.86, p = .02). Moreover, depressive symp-
toms declined significantly from baseline to the 26-week
post assigned quit-date (B = − 1.53, SE = 0.68, p = .03).
Interestingly, one RCT study found a reduction in de-
pression over time but only among abstainers regardless
of the treatment condition [49]. Participants who
remained abstinent at 12-month follow-up reported sig-
nificantly fewer depressive symptoms, compared to
substance users (B = − 5.74, SE = 1.65, 95% CI = − 9.10, −
2.58). In addition, they found a significant decrease in
depressive symptoms from pre-treatment to 12-months
post-treatment only in abstainers (B = − 0.43, SE = 0.11,
95% CI = − 0.65, − 0.22).
Discussion
The aim of this systematic review was to examine if BA
has an effect in reducing substance use and depression.
Previous research has shown that reinforcement pro-
cesses play a central role in the onset, maintenance, and
recovery from depression [38] and SUDs [18]. Both dis-
orders share features such as a reduced engagement in
enjoyable non-drug-related activities/reinforcement or
the presence of anhedonia, defined as a diminished
interest/pleasure in response to previously rewarding ac-
tivities [23, 51]. Since the main focus of BA is to increase
healthy and rewarding activities [37], the potential use of
BA in substance use treatment is justified.
Overall, the results of the present review were mixed. Al-
though some studies indicated that BA reduced signifi-
cantly substance use [47, 49] and depression [47], the effect
sizes were moderate [43, 46]. In addition, most of studies
included did not reach statistical significance [43, 46, 50].
Since the majority of the studies were pilot [43–45, 47] or
feasibility studies [46], they may be underpowered to detect
significant differences. In fact, the only well powered RCT
[49] showed that BA significantly reduced substance use.
Interestingly, BA has demonstrated its effectiveness for
depression treatment [34]; although for people with sub-
stance use and depression, BA effect seems to be larger
for substance use than for depression when compared
against a control condition. It is possible that substance
use outcomes (e.g., abstinence status) after treatment or
during the follow-up period had an impact in depression
outcomes, since previous research has found an associ-
ation between substance use abstinence and depressive
symptoms reduction [52–54]. Given that the majority of
Table 2 Ratings of methodological quality by EPHPP tool
Selection bias Study design Confounders Blinding Data collection Withdrawals Global rating
Daughters et al. (2018) [49] Strong Strong Strong Strong Strong Strong Strong
Gonzalez-Roz et al. (2018) [50] Strong Strong Strong Weak Strong Strong Moderate
Busch et al. (2017) [43] Strong Strong Strong Weak Strong Strong Moderate
Delgadillo et al. (2015) [46] Moderate Strong Strong Moderate Strong Weak Moderate
Mimiaga et al. (2012) [48] Strong Moderate Weak Moderate Strong Strong Moderate
MacPherson et al. (2010) [47] Moderate Strong Strong Strong Strong Weak Moderate
Carpenter et al. (2008) [45] Moderate Strong Moderate Moderate Strong Moderate Moderate
Carpenter et al. (2006) [44] Weak Moderate Weak Weak Strong Moderate Weak

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Martínez-Vispo et al. Substance Abuse Treatment, Prevention, and Policy  (2018) 13:36 Page 9 of 13
studies have analyzed substance use and depression out-
comes separately, it would be interesting to analyze their
interaction in future studies. Moreover, as suggested by
Daughters et al. [49], research is needed to examine the
effect of BA-based interventions on primary versus sec-
ondary depression in people with comorbid substance
use and depression.
In addition, diverse factors could have influenced in the
results found. One of them could be the heterogeneity of
inclusion criteria for the different studies. For example,
Busch et al. [43] and Mimiaga et al. [48] included partici-
pants with a wide range of baseline depression scores,
from asymptomatic to individuals with severe symptom-
atology; whereas Carpenter et al. [44] and Carpenter et al.
[45] only included participants with a DSM-IV diagnosis
of major depression or dysthymic disorder. Measures for
depression were also heterogeneous (e.g., Beck Depression
Inventory-II; Hamilton Depression Scale; Montgomery–
Åsberg Depression Rating Scale; Patient Health Question-
naire), as well as the target population (e.g., Acute Coron-
ary Syndrome [ACS] patients, Human Immunodeficiency
Virus [HIV] uninfected men who have sex with men), the
treatment setting (e.g., inpatient cardiac units,
community-based methadone maintenance programs;
community drugs and alcohol treatment services), or the
different stages of drug use treatment. Control conditions,
type, length, and intensity also vary significantly across
studies. Carpenter et al. [45] used a structured psycho-
logical treatment as a comparison group (e.g., 24
face-to-face weekly sessions of relaxation intervention),
whereas Busch et al. [43] used a Standard-of-Care condi-
tion (e.g., one face-to-face session and five emails of
printed educational material about smoking cessation).
Baseline significant differences between groups could also
have influenced the results. In fact, in the study conducted
by Carpenter et al. [45], the Behavioural Therapy for De-
pression in Drug Dependence (BTDD) condition had a
greater proportion of opiate users (p ≤ .03), and in the
study conducted by Delgadillo et al. [46] baseline Severity
of Dependence Scale was also significantly higher in the
BA group (p = .03). Finally, the studies included in this re-
view used different BA treatment approaches. Concretely,
we found that two studies [44, 45] used an approach based
on Lewinsohn et al. conceptualization [55], two studies
[46, 48] used the Martell et al., BA approach [56], whereas
the remaining four studies [43, 47, 49, 50] used a modified
version of the brief behavioural activation treatment for
depression (BATD) [39]. All these approaches are based
on the principles of the behavioural model, share the use
of behavioural strategies, and focus on behaviour change
[40], but they have some differences. For example, the BA
conceptualization of Lewinsohn et al. [55] focuses on
assessing the relationship between mood and pleasant ac-
tivity level, and on increasing the frequency of pleasant
activities to facilitate positive interactions between the in-
dividual and the environment. The BA protocol of Martell
et al. [38] focuses on behaviour functional analysis (exam-
ining antecedents and consequences) in order to identify
behavioural avoidance patterns (e.g., avoid trying new ac-
tivities or avoid attending social events/activities), and in-
cludes the use of strategies as mental rehearsal, periodic
distraction or skill-training. In the case of the BATD
model of Lejuez et al. [39], it focuses on increasing
reinforcement for non-depressive behaviours (e.g.,
sport-related activities, social or leisure activities) empha-
sizing the personal value of these alternative behaviours.
Further research is needed to determine if different BA
treatment approaches have the same effects on depression
and substance use outcomes.
Other limitations of this review include: first, the
length of participants’ follow-ups. Only one study in-
cluded a 12 months follow-up [49], while the rest had
the longest follow-up at 24 weeks post-intervention,
which limited examining the long-term sustainability of
treatment effects. Second, since BA effectiveness has
been widely demonstrated in depression treatment [34,
57], we sought to investigate whether BA could improve
not only depression, but also substance use outcomes.
Thus, only studies that provided both outcomes were in-
cluded. For this reason, we excluded two studies exam-
ining the effects of a BA intervention, named LETS Act!,
on depression in standard inpatient substance abuse
treatment [58, 59]. Although they were excluded, the re-
sults of both studies suggest that the BA approach re-
duce depressive symptoms in this specific population,
and one of them [59] also found a significantly lower
percentage of individuals that dropped out of residential
substance abuse treatment in the LETS Act! condition.
These findings provide additional support to the positive
effects of the BA approach.
Regarding the quality of the studies, it is of note that
only one of the studies reached the qualification of strong
methodological quality [49]. Further high-quality studies
are needed to improve confidence in these findings and to
confirm the positive effect of BA both in substance use
outcomes and depression. In line with our results, a recent
overview about cognitive-behavioural therapies for sub-
stance use and depression disorders conducted by Vujano-
vic et al. [28] showed that, despite the growing evidence
supporting the effectiveness of integrated CBT for the
treatment of co-occurring SUD-depression, the scarce of
well-controlled studies limit their conclusions. Finally, six
of the eight studies were conducted in the United States,
which should be considered in the interpretation and
generalization of results, as it has not been tested in others
geographical and cultural settings.
Despite the limitations, this systematic review clearly de-
scribed and followed internationally accepted standards
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for the process of identifying studies. In addition,
despite that BA has demonstrated its effectiveness in
the treatment of depression treatment, this review
addresses its comorbidity with substance use. This is
a novel and relevant topic since depression influ-
ences SUDs recovery and relapse. In addition, SUDs
imply in many cases a lack of natural and alternative
reinforcers and activities that are meaningful in life
and provide a sense of purpose [35], which can have
an impact in substance use-related behaviour
change.
Although more research is needed to support the
effectiveness of BA for the treatment of substance use
and depression, the studies reviewed showed promis-
ing and suggestive data. Future studies are required
to investigate the mechanisms of action of BA, as
well as possible moderator variables that can have im-
pact in SUDs and depression outcomes. More re-
search is also needed to investigate whether the BA
model can just be applied to SUDs and whether the
reward-related processes in SUDs and depression are
as comparable as implied. For example, it is necessary
to elucidate whether there are differences between an-
ticipatory anhedonia (e.g., diminished subjective de-
sire, interest, and anticipation of pleasant stimulus/
activity) and consummatory anhedonia (e.g., inability
to experience pleasure in response to a pleasurable
stimulus/activity) in SUDs and depression, and if this
could influence treatment outcomes. Finally, future
studies should be conducted on cost-effectiveness of
this intervention approach, and on how BA can be
implemented into clinical and community settings.
Conclusions
The results of this systematic review suggest that BA
may help to improve substance use and depressive
symptoms. However, research into BA in substance
use and depression is at an early stage, and the ma-
jority of results are based on pilot studies with meth-
odological limitations. Thus, they should be
interpreted with caution. Given the high comorbidity
of substance use and depressive symptoms, and the
preliminary results indicating that BA may be a useful
intervention for this population, more research is re-
quired to establish BA effectiveness. Future studies
should be conducted adhering to standard reporting
guidelines and using rigorous methodology including
sample size calculations, adequate methods of
randomization, intention-to-treat analysis, and longer
follow-up periods.
In summary, BA is a promising option that could
be easily integrated in substance use treatments due
to its brevity and parsimony. BA could be imple-
mented in treatment and community programs that
make accessible and provide the opportunity to par-
ticipate and engage in social, healthy, and cultural ac-
tivities, offering more options for substance-free
sources of reinforcement. Compromise and economic
resources of governments and policymakers’ result es-
sential to make possible to deal with substance use
and depression, as these problems have an enormous
cost at personal, social, and economic levels.
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